Stock Pick - Cipla Ltd.


Super Moderator
Stock Pick - Cipla Ltd.

Two Cipla Aids Medicines Back on WHO Prequalification List

Domestic pharma major, Cipla, declared its 2QFY05 and 1HFY05 results. The topline grew by 29% in the quarter led by a good performance in both formulation exports as well as in the domestic pharma market. The bottomline has grown by 38%, which was basically due to expansion of margins.

About the companys business?

Cipla is the largest pharma company in the retail market according to the latest ORG survey. The company has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by the US FDA and the formulation facilities have been approved by the Medicine Control Agency - UK, the Medicine Control Council - South Africa, the Therapeutic Goods Administration - Australia and other international agencies. On exports front, the company has strategic alliance with major generic manufactures such as Watson, Mylan, Barr and Ivax for supply of bulk drugs. It has a very wide product range in domestic market, which includes antibiotics, anti-bacterial, anti-asthmatics, anti-inflammatory, antiretroviral, anthelminites, anti-cancer and cardiovascular. In domestic formulation market, antibiotics are the mainstays. It also concentrates on developing specialty bulk drugs for export markets.

What has driven performance in 1QFY05?

Outperforms the domestic market: Sales in the domestic market grew by 25%, thus beating the domestic market growth of 7.5% by quite a margin. Export of formulations has increased by 76%, led by higher contribution from the European and some non-regulated markets. However, supply of API's has shown decline of 10% in 2QFY05 basically due to lower API supply to the regulated markets. Exports now contribute 39% to the companys revenues (36% in the same quarter last year).

Operating margin expands: Good growth in the topline helped the company to expand margins. The benefits from economies of scale were visible with lower raw material cost and lower staff cost as a percentage of sales. Also, better product and marketing mix, helped company to expand its margin by 290 basis points.

See attached chart for trading signal, profit target and stop loss level.


Similar threads

Broker Special Offers

Intraday Higher Leverage

Save up to 90% in brokerage and get higher leverage for intraday trades.

Are you a day trader?